DARMSTADT, Germany, June 11, 2018 /PRNewswire/ — Primary endpoints met in two clinical trials for investigational targeted therapy, tepotinib, as a monotherapy in MET-positive, advanced hepatocellular carcinoma (HCC) with Child-Pugh Class A liver function These data provide further evidence of tepotinib activity in patients with MET-positive advanced cancers Given
May 29, 2018 – Presentations for investigational Cladribine Tablets include analyses of NEDA and MRI outcomes in patients with relapsing MS – MS in the 21st Century to debut ‘My MS Priorities,’ a new tool to help improve patient-HCP dialogue
May 17, 2018 Merck today announced new data from a number of high priority clinical development programs across its oncology portfolio to be presented at this year’s American Society of Clinical Oncology Annual Meeting. Two-year safety and efficacy data in
16 MAY 2018 | DARMSTADT, GERMANY Merck today announced a collaboration with Washington University in St. Louis, Missouri, USA, that could lead to the optimizing of nutritional supplements to restore a healthy gut microbial community. • Collaboration with Washington University on gut
03 MAY 2018 | DARMSTADT, GERMANY Merck family representative Frank Stangenberg-Haverkamp: “Time and again, this company has reinvented itself. And we will continue to develop Merck further in the future as well.” Stefan Oschmann, Chairman of the Executive Board: “Merck has been
02 MAY 2018 | DARMSTADT, GERMANY Post-hoc analysis from the 2-year CLARITY study demonstrated that Mavenclad reduced the risk of 6-month EDSS progression by 47% vs placebo Patients with highly active multiple sclerosis had an even greater treatment effect, reducing the risk
02 MAY 2018 | DARMSTADT, GERMANY Agreement enables Merck to further develop abituzumab through a novel risk-sharing collaboration agreement SFJ Pharmaceuticals Group to develop abituzumab as a first-line treatment for metastatic colorectal cancer (mCRC) in combination with Erbitux® and chemotherapy Clinical program
Merck held its 23rd Annual General Meeting today. The company’s 350th anniversary was one of the overriding themes. 27 APR 2018 | DARMSTADT, GERMANY 23rd Annual General Meeting in Frankfurt am Main A look back at business developments and strategic moves in